1622327-37-0
1622327-37-0 structure
- Name: Laprituximab emtansine
- Chemical Name: Laprituximab emtansine
- CAS Number: 1622327-37-0
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways JAK/STAT Signaling EGFR
- Create Date: 2023-04-18 12:18:06
- Modify Date: 2024-04-05 19:49:45
-
Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research[1][2][3].
| Name | Laprituximab emtansine |
|---|
| Description | Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
HER1 |
| In Vitro | Laprituximab emtansine 显示出对 HNSCC 细胞系的抗克隆形成和抗增殖活性，IC50s 为 0.003 nM-1.74 nM[3]。 Laprituximab emtansine 对 NSCLC 细胞系和 EGFR 突变 HCC827 细胞系具有细胞毒性[2]。 Cell Viability Assay[3] Cell Line: PBMCs from humans, rhesus and cynomolgus animals Concentration: 0-1 μg/mL approximately Incubation Time: 3 days Result: Inhibited rCD154-induced proliferation of PBMCs with IC50s of 0.02, 0.03, and 0.01 μg/mL, respectively. |
| In Vivo | Laprituximab emtansine (1-5 mg/kg，静脉注射) 在 EGFR 阳性 SCCHN 异种移植模型中导致肿瘤消退[4]。 Animal Model: EGFR-positive SCCHN xenograft model[4] Dosage: 1, 2.5, 5 mg/kg Administration: i.v. Result: Resulted tumor regression with a minimally efficacious dose of 1 mg/kg, and highly active at 2.5 and 5 mg/kg. |
| References |
| No Any Chemical & Physical Properties |